drugset / Trial / NCT07792941
A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20
NaSingle-groupOpen-labelBasic science
Summary
This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.
Timeline
- Start
- 2026-08-27
- Primary completion
- 2027-02-11
- Completion
- 2027-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilrekimig | Monoclonal antibody | — | Subcutaneous |
| Background | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.